Serum Levels of 25(OH) Vitamin D3 and Clinical Manifestation of First Demyelinating Attack

Document Type : Original Article (s)

Authors

1 Student of Medicine, Isfahan Neuroscience Research Center AND Isfahan Research Committee of Multiple Sclerosis, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Isfahan Neuroscience Research Center AND Isfahan Research Committee of Multiple Sclerosis, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Epidemiologist, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. The role of vitamin D against onset and progression of multiple sclerosis is well-recognized. In this study, we evaluated the serum levels of 25(OH) vitamin D3 in patients with clinically isolated syndrome with the manifestation of optic neuritis, brain stem, and spinal cord syndrome.Methods: In this cross sectional study, a total of 104 cases were enrolled (35 patients with optic neuritis, 35 patients with spinal cord syndrome, and 34 patients with brain stem syndrome). The serum levels of 25(OH) vitamin D3 were measured in all patients.Findings: Mean serum level of 25(OH) vitamin D3 was 11.30 ± 6.82, 14.00 ± 10.27, and 18.65 ± 13.15 ng/ml in patients with spinal cord syndrome, optic neuritis, and brain stem syndrome, respectively. Serum level of 25(OH) vitamin D3 was significantly lower in patients with spinal cord syndrome in comparison to patients with optic neuritis or brain stem syndrome (P = 0.010).Conclusion: According to previous studies, the association between poor serum levels of 25-OH vitamin D3 and increased relapse rate and magnetic resonance imaging (MRI) lesions in patients with multiple sclerosis has been reported. Furthermore, lower 25-OH vitamin D3 levels are associated with increased risk of the disease later in life. In our study, different serum levels of 25-OH vitamin D3 was associated with variable clinical manifestations of the disease. The status of 25-OH vitamin D3 appears to play an important role since the very early stages of disease.

Keywords

References

  1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-302.
  2. McKay KA, Jahanfar S, Duggan T, Tkachuk S, Tremlett H. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology 2017; 61: 189-212.
  3. Hartl C, Obermeier V, Gerdes LA, Brugel M, von KR, Kumpfel T. Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients. J Neurol Sci 2017; 375: 160-4.
  4. Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, et al. Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler 2016; 22(6): 753-60.
  5. Pakpoor J, Ramagopalan S. Evidence for an association between vitamin D and multiple sclerosis. Curr Top Behav Neurosci 2015; 26: 105-15.
  6. Rito Y, Flores J, Fernandez-Aguilar A, Escalante-Membrillo C, Barboza MA, Amezcua L, et al. Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background. Acta Neurol Belg 2017.
  7. Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh) 2015; 20(4): 329-35.
  8. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012; 11(2): 157-69.
  9. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015; 21(8): 1013-24.
  10. Muris AH, Rolf L, Broen K, Hupperts R, Damoiseaux J, Smolders J. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. J Steroid Biochem Mol Biol 2016; 164: 254-7.
  11. Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol 2016; 23(2): 327-32.
  12. Bettencourt A, Boleixa D, Reguengo H, Samoes R, Santos E, Oliveira JC, et al. Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal. J Steroid Biochem Mol Biol 2017. [Epub ahead of print].
  13. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006; 27(2): 455-61.
  14. Hovsepian S, Amini M, Aminorroaya A, Amini P, Iraj B. Prevalence of vitamin D deficiency among adult population of Isfahan City, Iran. J Health Popul Nutr 2011; 29(2): 149-55.
  15. Yeshokumar AK, Saylor D, Kornberg MD, Mowry EM. Evidence for the Importance of Vitamin D Status in Neurologic Conditions. Curr Treat Options Neurol 2015; 17(12): 51.
  16. Bermudez-Morales VH, Fierros G, Lopez RL, Martinez-Nava G, Flores-Aldana M, Flores-Rivera J, et al. Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults. J Neuroimmunol 2017; 306: 20-4.
  17. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol 2015; 98(2): 240-5.
  18. Sandberg L, Bistrom M, Salzer J, Vagberg M, Svenningsson A, Sundstrom P. Vitamin D and axonal injury in multiple sclerosis. Mult Scler 2016; 22(8): 1027-31.
  19. Ramagopalan SV, Byrnes JK, Dyment DA, Guimond C, Handunnetthi L, Disanto G, et al. Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. J Hum Genet 2009; 54(9): 547-9.
  20. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 2013; 70(5-6): 356-63.
Journal of Isfahan Medical School
Volume 36, Issue 465 - Serial Number 465
January and February 2018
Pages 22-27

Files

History

  • Receive Date: 31 December 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics